Travere Therapeutics (TVTX) Net Margin (2014 - 2026)

Travere Therapeutics has reported Net Margin for 13 years, with the latest figure at 0.39% in Q1 2026.

• For the quarter ending Q1 2026, Net Margin changed N/A year-over-year to 0.39%; the trailing twelve-month figure through Mar 2026 stood at 34.55% (down 3425.0% YoY), and the FY2025 full-year result was 265.75%, up 26615.0% from the prior year.
• Net Margin for Q1 2026 stood at 0.39%, up from 7.03% in the prior quarter.
• The five-year high for Net Margin was 646.92% in Q3 2023, with the low at 7.03% in Q4 2025.
• Historically, Net Margin has averaged 64.78% across 5 years, with a median of 12.34% in 2022.
• Annual changes were most pronounced in 2023 — Net Margin soared 59561 bps — and 2024, when it sank 64702 bps.
• Travere Therapeutics' Net Margin stood at 67.53% in 2022, then plunged by 105 bps to 3.5% in 2023, then surged by 100 bps to 0.01% in 2024, then plunged by 131473 bps to 7.03% in 2025, then soared by 94 bps to 0.39% in 2026.
• The last three Net Margin figures came in at 0.39% (Q1 2026), 7.03% (Q4 2025), and 0.01% (Q4 2024), per Business Quant data.